GaoRong Technology Secures Tens of Millions of RMB in Pre-A Funding to Advance Minimally Invasive Interventional Surgical Robotics

On September 16, a company specializing in robotic systems for minimally invasive interventional oncology proceduresGaorong TechnologyAnnounced the completion of a Pre-A financing round worth tens of millions of yuan,Led by Xiao Miao Lang Cheng, with follow-on investments from Bangming Capital and others,Existing Shareholder Haemader Venture Capital Continues to Increase Its Stake, with Shien Capital serving as the exclusive financial advisor.

This round of financing will accelerate Gaorong Technology’s progress in talent acquisition, product development, clinical trials, and market launch, enabling doctors and patients to benefit earlier from robot-assisted minimally invasive interventional tumor procedures.

Gaorong Technology, established in August 2019, is a surgical robotics company featuring an internationally leading artificial intelligence service platform. The company’s first product is a robotic system for minimally invasive interventional oncology procedures. Within two years of its founding, the company rapidly achieved platformization of its AI technology and, leveraging this foundation, completed multiple iterations of its surgical robotics products.

Since the advent of Intuitive Surgical, surgical robots have been continuously transforming traditional surgical practices, with the pace of change accelerating. According to data from third-party consulting firm Mordor Intelligence, the global market size for surgical robots was approximately USD 4.4 billion in 2020 and is projected to reach USD 9.6 billion by 2026, representing a compound annual growth rate (CAGR) of 11.4%.

Unlike common surgical robot solutions based on collaborative robotic arms, Gaorong Technology’s surgical robot possesses fully independent intellectual property rights, spanning from the robot itself to its control software and overall solution. By deeply integrating with surgical scenarios, this surgical robot can precisely and rapidly assist surgeons in completing procedures, addressing issues such as reliance on manual experience during clinical practice, improving surgical efficiency, and reducing surgical risks.

In the field of robotic systems for tumor puncture and interventional procedures, only a few companies abroad, such as XACT Robotics, have the capability to provide such products. Gaorong Technology’s tumor puncture and interventional surgical robot is poised to fill the domestic gap in this area.

In addition to surgical robot systems, Gaorong has also developed supporting products such as an auxiliary diagnosis and treatment planning system, covering three major surgical scenarios: preoperative planning, intraoperative navigation, and postoperative assessment.

Dr. Zhang Min is the founder of Gaorong Technology. Prior to establishing the company, he served as Chief Data Scientist in the product division at GE Healthcare’s U.S. headquarters, where he led the development of a general artificial intelligence platform for the company. Before joining GE Healthcare, Dr. Zhang was an Assistant Professor in the Department of Radiology at the Mayo Clinic, ranked #1 in the United States. As a core member, he helped build the Mayo Intelligent Imaging Data Platform, which integrates over 100 imaging devices and has been deployed across 25 hospitals within the Mayo Clinic Health System. Dr. Zhang has multiple AI models cleared by the U.S. Food and Drug Administration (FDA). He has engaged in product-oriented collaborations on AI healthcare projects with the Center for Data Science at Massachusetts General Hospital and the University of California, San Francisco (UCSF). A board-certified Clinical Informaticist in the United States, Dr. Zhang holds more than 20 patent applications in North America. Currently, he also serves as a Researcher at Fudan University Ningbo Institute and as an Adjunct Professor at the Mayo-ASU Laboratory for Innovations in Medical Image Analysis.

Since its establishment, Gaorong Technology has continuously garnered market attention and recognition through technological innovation. Today, Gaorong Technology’s services have been adopted by dozens of Grade 3A hospitals across China, and the company has established business collaborations with numerous top-tier hospitals abroad.

When discussing the reasons for investing in Gaorong Technology,Fang Zhenghao, Managing Partner at Xiao Miao Lang Cheng“The Xiaomiao Langcheng team has long focused on investment opportunities at the intersection of information technology, digitalization, and the healthcare industry. Surgical robots represent a highly challenging cross-disciplinary field encompassing artificial intelligence, medical imaging, and mechanical engineering, which we view favorably. Dr. Zhang Min, founder of Gaorong Technology, possesses forward-thinking expertise in AI R&D at the top-ranked hospital in the United States and a profound understanding of hospital needs. He also brings proven capability and experience in product commercialization and implementation from leading medical device companies. We have engaged in in-depth exchanges with the Gaorong Technology team as early as two years ago. During this period, we observed the company rapidly identify its business direction; its surgical robot products have undergone multiple rounds of iteration in a short time, and it has established collaborations with numerous Grade A tertiary hospitals across China. We are very optimistic about Gaorong Technology and are committed to supporting the company’s growth over the long term.”

For this round of financing,Dr. Zhang Min, Founder and Chairman of Gaorong TechnologyHe stated, “We are grateful for the trust placed in us by investors such as Xiao Miao Lang Cheng, Bangming Capital, and Haimaide Venture Capital. Their investment represents significant support for Gaorong Technology. Due to their technical difficulty and complexity, surgical robots have long been regarded as the ‘crown jewel’ of the robotics industry. Following the completion of this financing round, we will further attract top global talent and continue to increase our R&D investment, thereby empowering physicians and helping patients achieve precise treatment more quickly and effectively.”

Shanghai Xiaomiao Langcheng Investment Management Co., Ltd. (hereinafter referred to as “Xiaomiao Langcheng”) is a venture capital investment management platform under Zizhu High-Tech Park, which is controlled by Zijiang Group. As a pioneer in domestic early- to mid-stage technology investment adopting the “Value Discovery + Value-Added Services” model, it focuses on investing in innovative and high-growth sci-tech enterprises represented by ABCII (Cloud Computing, Big Data, Internet of Things, Artificial Intelligence, and Intelligent Technology Applications).

The core management team of Xiaomiao Langcheng possesses extensive experience in equity investment management and capital operations for listed companies, with an investment success rate ranking among the top in the equity investment industry (to date, more than 10 portfolio companies have completed IPOs, and nearly 10 have exited through M&A). As of now, funds managed by Xiaomiao Fund and its subsidiary Xiaomiao Langcheng have cumulatively invested in over 70 technology enterprises, including Gaorong Technology, Aochuang Photonics, Saiduo Intelligence, Shenqing Technology, Bintong Intelligence, Yizhun Intelligence, ZStack, Qingyan Precision, Feiwei Information, Flexiv Robotics, Parala Software, Tongchuang Yongyi, and Dingna Automation.

Bangming Capital, established in 2011, is a professional venture capital firm that has long adhered to the philosophy of value investing and focuses on investing in “technology + growth” enterprises. Since its inception, Bangming Capital has been dedicated to key technologies and technological innovations in the fields of electronic information semiconductors, healthcare, and energy conservation and environmental protection. Upholding the spirit of “long-termism” and the principles of value discovery and value creation, we are committed to growing alongside China’s most promising sci-tech innovators and entrepreneurs, jointly building their innovative ventures.

HiMed, the HiMai Medical Innovation Cooperation Platform, was founded by 35 successful entrepreneurs, investors, and professors from the medical industry in the Shanghai Zhangjiang area. Leveraging the founders’ own entrepreneurial success experiences and extensive industry resources, the platform focuses deeply on medical collaboration, technology transfer, incubation, and early-stage investment. Among its initiatives, the HiMed Fund is an angel investment platform managed by a GP company established by several of the founders, with some founders also participating as LPs. The fund currently manages two vintages and has invested in more than twenty early-stage medical startup projects.